AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00053508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM1000
Description: Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
Study NCT00053508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccinia virus (calf lymph) smallpox vaccine: Dryvax
Description: group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
Study NCT01290198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)
Description: At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
Study NCT01046825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: COPAD
Description: Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.
Study NCT01046825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: COP, COPD M3, CYM
Description: GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.
Study NCT01046825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: COP, COPADM8, CYVE
Description: Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.
Study NCT04458987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert patient in addictology
Description: EP's Intervention, with patients hospitalized for addiction withdrawal. These are weekly individual interviews, in room, proposed by the EPs to inpatients.~The content of the intervention will be defined trough the results of step one of the study.
Study NCT03298633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
Study NCT03298633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IVF
Description: All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
Study NCT00676897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40mg PO or NGT
Study NCT00676897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn Starch
Study NCT03106298 — intervention group
Intervention type: DRUG
Intervention: Iron Sucrose
Description: All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
Study NCT01774019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Study NCT02883179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine injection
Description: anhydrous solution
Study NCT02883179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine-prilocaine cream
Description: topical cream
Study NCT00694733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Normal saline injection IM monthly for 4 months
Study NCT00694733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo Lupron/Aromatase inhibitor
Description: Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
Study NCT00694733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo Lupron/placebo
Description: Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
Study NCT00694733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Cream 1ml applied twice daily for four months
Study NCT00694733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen cream
Description: Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
Study NCT02742792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.
Study NCT02742792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advice on Lifestyle
Description: Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
Study NCT04301115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attachment
Description: unilateral attachment from rehine 83
Study NCT04301115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bridge
Description: tooth implant supported bridge
Study NCT04301115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL
Description: conventional metalic partial denture
Study NCT00716066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT00716066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous or syngeneic stem cell transplantation
Study NCT00716066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT00716066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT00716066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00716066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00716066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT00716066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous or syngeneic stem cell transplantation
Study NCT00716066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT00716066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syngeneic Bone Marrow Transplantation
Description: Undergo syngeneic bone marrow transplantation
Study NCT04883021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Target Theta Burst Stimulation
Description: TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold.
Study NCT01510002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy
Description: Extracapsular total thyroidectomy
Study NCT01510002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy + prophylactic central neck dissection
Description: Extracapsular total thyroidectomy plus prophylactic central neck dissection
Study NCT02073253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
Study NCT03500666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot
Description: Robot lateral neck lymph node dissection
Study NCT03500666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total endoscopic
Description: Total endoscopic lateral cervical lymph node dissection
Study NCT00643435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing interviewing techniques training
Description: Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
Study NCT00643435 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
Study NCT01709955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucomannan
Description: 750 MG of Glucomannan in capsule form
Study NCT01709955 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 750 mg of Cellulose powder in a capsule form
Study NCT02678364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control eggs
Description: Control eggs containing no additional vitamin D beyond norm
Study NCT02678364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 eggs
Description: Vitamin D3-biofortified eggs
Study NCT02678364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25-Hydroxyvitamin D3 eggs
Description: 25-Hydroxyvitamin D3-biofortified eggs
Study NCT00397020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex ER
Description: Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
Study NCT00397020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine
Description: Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
Study NCT02406495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: filcon IV 1
Description: contact lens
Study NCT02406495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocufilcon D
Description: contact lens
Study NCT01136447 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound
Description: Block catheter will be introduced using ultraosound
Study NCT01136447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Block catheter will be introduced using ultraosound
Study NCT02163798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week instructor-led Tai Chi training program
Description: A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
Study NCT02163798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week instructor-led brisk walking training program
Description: A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
Study NCT04421313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Fiber Supplementation
Description: 12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)
Study NCT04421313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Fiber Supplementation
Description: 12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)
Study NCT01792596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pasta with protein
Description: Pasta with Protein
Study NCT01792596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pasta with Fiber
Description: Pasta with Fiber
Study NCT01792596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pasta
Description: Pasta
Study NCT02005393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FICE Image Acquisition followed by NBI Image Acquisition
Description: Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
Study NCT00822666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
Study NCT00822666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
Study NCT01168245 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-NICE-System
Description: sham TMS and sham cognitive training
Study NCT01168245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICE-System
Description: TMS combined with cognitive training
Study NCT03060213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW)
Description: FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 ml DexaGalen 4 mg/ml
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (Control)
Description: 4 ml NaCl 9 mg/ml
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Premedication and as needed after operation
Study NCT01290198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)
Description: At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
Study NCT00750256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
Study NCT03173365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: 1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Premedication and as needed after operation
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EtoriCoxib
Description: Premedication and first 2 postoperative days.
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EtoriCoxib
Description: Premedication and first 2 postoperative days.
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: In brachial plexus block
Study NCT03011905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: In brachial plexus block
Study NCT01624298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Focused Cognitive Behavioral Therapy
Description: TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
Study NCT01080391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally or IV on days 1, 8, 15, 22
Study NCT01080391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg orally or IV on days 1, 8, 15, 22
Study NCT01080391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg orally on days 1-21
Study NCT01080391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25 mg orally on days 1-21
Study NCT01080391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20 mg/m², 27 mg/m² intravenously
Study NCT02065063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.
Study NCT02065063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
Study NCT00114738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (R)
Description: Rituximab is given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.
Study NCT00114738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
Study NCT00114738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (B)
Description: Bortezomib is given alone for one cycle.